Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This study observed that the compound EM-402 reduced 5α-reductase activity and sebaceous gland size in the flank organs and ears of hamsters, indicating potent localized anti-androgenic effects without systemic action.

This study developed a new, simple, and economical RP-TLC method with densitometry that is suitable for routine analysis of finasteride in tablet dosage form, meeting analytical validation criteria.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.

This study found that 4 weeks of finasteride treatment significantly decreased DHT levels in bald scalp to levels similar to hair-containing scalp in men with male pattern baldness.

In this study, dutasteride was found to be effective and safe in treating androgenetic alopecia in men who did not respond to finasteride, with improvements observed in hair loss and quality over 24 weeks.

Low-dose finasteride may cause muscle weakness and eye issues, but stopping the drug can lead to recovery.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

The study concluded that poly(propylene carbonate maleate) microspheres effectively encapsulated finasteride, achieving a biphasic release with prolonged drug release over 5-6 weeks in vitro.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

Researchers developed a quick and sensitive way to measure finasteride in blood using a small sample size.

This study found that dutasteride treatment in pregnant mares significantly increased progesterone concentrations but did not alter gestational length or neonatal outcomes.

This study identified eight isoflavone derivatives as potential nonsteroidal inhibitors of rat 5α-reductase using a pharmacophore model in virtual screening.

This study reports that five new progesterone derivatives demonstrated inhibitory activity against the 5α-reductase enzyme and binding affinity for the androgen receptor in an in vitro hamster model.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.

This study concluded that serum Adiol-G levels generally parallel testosterone levels and, therefore, do not effectively serve as a marker of peripheral androgen excess in women with androgenic symptoms.

In this study, researchers found that finasteride inhibits progesterone synthesis by blocking cholesterol side-chain cleavage in mouse-derived MA-10 Leydig cells, but this effect may not be evident in human or rat cells.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

In this study, researchers developed a sensitive assay to measure the inhibition of steroid 5-α reductase (5AR) by chemicals like finasteride and dutasteride, revealing species-specific differences in inhibitor efficacy between human and fish cell lines.

This study found that both finasteride and flutamide effectively reduce hirsutism in women with polycystic ovary syndrome or idiopathic hirsutism, but flutamide was more effective.

This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.